An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens

Abstract The increasing incidence of antibiotic resistance and the decline in the discovery of novel antibiotics have resulted in a global health crisis, particularly, for the treatment of infections caused by Gram-negative bacteria, for which therapeutic dead-ends are alarming. Here, we identify an...

Full description

Saved in:
Bibliographic Details
Main Authors: Seav-Ly Tran, Lucie Lebreuilly, Delphine Cormontagne, Samantha Samson, Thu Ba Tô, Marie Stosskopf, Rozenn Dervyn, Anne Grießhammer, Jacobo de la Cuesta-Zuluaga, Lisa Maier, Thierry Naas, Simona Mura, Didier Rognan, Julien Nicolas, Gwenaëlle André, Nalini Ramarao
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-58282-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850042909152247808
author Seav-Ly Tran
Lucie Lebreuilly
Delphine Cormontagne
Samantha Samson
Thu Ba Tô
Marie Stosskopf
Rozenn Dervyn
Anne Grießhammer
Jacobo de la Cuesta-Zuluaga
Lisa Maier
Thierry Naas
Simona Mura
Didier Rognan
Julien Nicolas
Gwenaëlle André
Nalini Ramarao
author_facet Seav-Ly Tran
Lucie Lebreuilly
Delphine Cormontagne
Samantha Samson
Thu Ba Tô
Marie Stosskopf
Rozenn Dervyn
Anne Grießhammer
Jacobo de la Cuesta-Zuluaga
Lisa Maier
Thierry Naas
Simona Mura
Didier Rognan
Julien Nicolas
Gwenaëlle André
Nalini Ramarao
author_sort Seav-Ly Tran
collection DOAJ
description Abstract The increasing incidence of antibiotic resistance and the decline in the discovery of novel antibiotics have resulted in a global health crisis, particularly, for the treatment of infections caused by Gram-negative bacteria, for which therapeutic dead-ends are alarming. Here, we identify and characterize a molecule, NM102, that displays antimicrobial activity exclusively in the context of infection. NM102 inhibits the activity of the non-essential Mutation Frequency Decline (Mfd) protein by competing with ATP binding to its active site. Inhibition of Mfd by NM102 sensitizes pathogenic bacteria to the host immune response and blocks infections caused by the clinically-relevant bacteria Klebsiella pneumoniae and Pseudomonas aeruginosa, without inducing host toxicity. Finally, NM102 inhibits the mutation and evolvability function of Mfd, thus reducing the bacterial capacity to develop antimicrobial resistance. These data provide a potential roadmap for the development of drugs to combat antimicrobial resistance.
format Article
id doaj-art-9063f78f3dca4da7ab0819da0309ed4b
institution DOAJ
issn 2041-1723
language English
publishDate 2025-04-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-9063f78f3dca4da7ab0819da0309ed4b2025-08-20T02:55:23ZengNature PortfolioNature Communications2041-17232025-04-0116111910.1038/s41467-025-58282-8An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogensSeav-Ly Tran0Lucie Lebreuilly1Delphine Cormontagne2Samantha Samson3Thu Ba Tô4Marie Stosskopf5Rozenn Dervyn6Anne Grießhammer7Jacobo de la Cuesta-Zuluaga8Lisa Maier9Thierry Naas10Simona Mura11Didier Rognan12Julien Nicolas13Gwenaëlle André14Nalini Ramarao15Université Paris-Saclay, INRAE, Micalis InstituteUniversité Paris-Saclay, INRAE, Micalis InstituteUniversité Paris-Saclay, INRAE, Micalis InstituteUniversité Paris-Saclay, INRAE, Micalis InstituteUniversité Paris-Saclay, INRAE, Micalis InstituteUniversité Paris-Saclay, INRAE, Micalis InstituteUniversité Paris-Saclay, INRAE, Micalis InstituteInterfaculty Institute of Microbiology and Infection Medicine, University of TübingenInterfaculty Institute of Microbiology and Infection Medicine, University of TübingenInterfaculty Institute of Microbiology and Infection Medicine, University of TübingenTeam ReSIST, INSERM U1184, School of Medicine Université Paris-Saclay, LabEx LERMIT, Assistance Publique/Hôpitaux de Paris, French NRC for Carbapenemase-Producing Enterobacterales. Bicêtre HospitalUniversité Paris-Saclay, CNRS, Institut Galien Paris-SaclayUniversité de Strasbourg, CNRS, UMR 7200 LiTUniversité Paris-Saclay, CNRS, Institut Galien Paris-SaclayUniversité Paris-Saclay, INRAE, MaIAGEUniversité Paris-Saclay, INRAE, Micalis InstituteAbstract The increasing incidence of antibiotic resistance and the decline in the discovery of novel antibiotics have resulted in a global health crisis, particularly, for the treatment of infections caused by Gram-negative bacteria, for which therapeutic dead-ends are alarming. Here, we identify and characterize a molecule, NM102, that displays antimicrobial activity exclusively in the context of infection. NM102 inhibits the activity of the non-essential Mutation Frequency Decline (Mfd) protein by competing with ATP binding to its active site. Inhibition of Mfd by NM102 sensitizes pathogenic bacteria to the host immune response and blocks infections caused by the clinically-relevant bacteria Klebsiella pneumoniae and Pseudomonas aeruginosa, without inducing host toxicity. Finally, NM102 inhibits the mutation and evolvability function of Mfd, thus reducing the bacterial capacity to develop antimicrobial resistance. These data provide a potential roadmap for the development of drugs to combat antimicrobial resistance.https://doi.org/10.1038/s41467-025-58282-8
spellingShingle Seav-Ly Tran
Lucie Lebreuilly
Delphine Cormontagne
Samantha Samson
Thu Ba Tô
Marie Stosskopf
Rozenn Dervyn
Anne Grießhammer
Jacobo de la Cuesta-Zuluaga
Lisa Maier
Thierry Naas
Simona Mura
Didier Rognan
Julien Nicolas
Gwenaëlle André
Nalini Ramarao
An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens
Nature Communications
title An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens
title_full An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens
title_fullStr An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens
title_full_unstemmed An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens
title_short An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens
title_sort anti virulence drug targeting the evolvability protein mfd protects against infections with antimicrobial resistant eskape pathogens
url https://doi.org/10.1038/s41467-025-58282-8
work_keys_str_mv AT seavlytran anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT lucielebreuilly anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT delphinecormontagne anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT samanthasamson anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT thubato anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT mariestosskopf anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT rozenndervyn anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT annegrießhammer anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT jacobodelacuestazuluaga anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT lisamaier anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT thierrynaas anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT simonamura anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT didierrognan anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT juliennicolas anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT gwenaelleandre anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT naliniramarao anantivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT seavlytran antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT lucielebreuilly antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT delphinecormontagne antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT samanthasamson antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT thubato antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT mariestosskopf antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT rozenndervyn antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT annegrießhammer antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT jacobodelacuestazuluaga antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT lisamaier antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT thierrynaas antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT simonamura antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT didierrognan antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT juliennicolas antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT gwenaelleandre antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens
AT naliniramarao antivirulencedrugtargetingtheevolvabilityproteinmfdprotectsagainstinfectionswithantimicrobialresistanteskapepathogens